Roche/Genentech
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 11 disclosed transactions, Roche/Genentech concentrates its licensing activity in Oncology, Other, and Metabolic. Roche/Genentech pays a 1.50x premium over market median. Their most common deal structure is Collaboration, with an average disclosed value of $2.3B. Most recent activity: 2026.
Pipeline coverage & gaps
Roche/Genentech has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 6 | $211M | $3.2B |
| License | 5 | $224M | $1.2B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Earendil bispecific-antibody platform | Earendil Labs | oncology | discovery | $55M | $1.5B |
| 2026 | HM17321 | Hanmi Pharmaceutical | Obesity | phase_1 | $190M | $2.3B |
| 2026 | — | Astex Pharmaceuticals | Breast cancer | discovery | $25M | $490M |
| 2025 | — | Caris Life Sciences | Solid tumors (novel oncology target discovery) | discovery | $25M | $1.1B |
| 2025 | neurodegenerative programs | Sangamo | neurodegenerative diseases | preclinical | $50M | $50M |
| 2023 | OpRegen (RG6501) | Lineage Cell Therapeutics | Dry AMD, geographic atrophy | phase_2 | $50M | $670M |
| 2022 | Vixarelimab (KIN-324) | Kiniksa Pharmaceuticals | giant cell arteritis | phase_2 | $80M | $680M |
| 2021 | — | Recursion Pharmaceuticals | neuroscience and oncology | discovery | $150M | $12.7B |
| 2020 | Pralsetinib (GAVRETO; BLU-667) | Blueprint Medicines | RET-altered medullary thyroid cancer and other RET-altered cancers | phase_1 | $775M | $1.7B |
| 2020 | Pralsetinib (Gavreto; BLU-667) | Blueprint Medicines | RET-altered thyroid cancer and other RET-altered solid tumors | phase_1 | $775M | $1.7B |
| 2020 | Multiple bispecific-antibody and CAR-T programs | Innovent Biologics | B-cell malignancies including follicular lymphoma | preclinical | — | $2.1B |
How this is computed
For each Roche/Genentech deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 2.609, clamped to [0.7, 1.5].